TesamorelinInterpret the evidence
Why a smaller waist did not establish improved cognition in an HIV trial
2 numbered sourcesSource years 2025, 2026
Peptide bonds connect amino acids into short chains called peptides. Some activate hormone pathways that can influence several organs. Tesamorelin is a 44-residue analogue of growth hormone–releasing hormone with a chemical group attached at its starting end. An older randomized trial asked whether tesamorelin changed thinking and memory measures in adults with HIV, abdominal obesity and neurocognitive impairment. [1, 2]
No recent primary trial answering that exact question was identified. In the 2025 study, the investigators enrolled 73 adults and assigned them to tesamorelin or standard care. The study was open-label and did not include a matching placebo. Its primary outcome was change on a collection of cognitive tests over six months. The researchers also followed waist circumference and other measures, including aspects of mood and daily functioning. [1]
Waist circumference declined in the group assigned tesamorelin under the study conditions. The main comparison did not show a statistically clear difference in cognitive performance between groups. Those findings can coexist because the measurements describe different outcomes. Waist circumference describes one aspect of body size. Cognitive tests examine abilities such as attention, memory or reasoning. A change in one measure cannot establish a change in the other. [1]
The investigators noted limitations, including limited statistical power and the absence of a placebo group. In a small study, the estimate of a group difference can be uncertain. An open-label design can also introduce differences in expectations or other experiences that are difficult to separate from the intervention. The study gives a direct comparison for the tested population and time frame, and leaves the effects of different study conditions unresolved. [1]
The approved U.S. indication for tesamorelin concerns excess abdominal fat in adults with HIV-associated lipodystrophy. The cognitive outcome was an investigated use in this trial. The observed change in waist circumference does not supply evidence of cognitive benefit on its own. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
